Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
| ACRV Stock | 6.02 0.61 11.28% |
Slightly above 55% of Acrivon Therapeutics,'s sophisticated investors are presently thinking to get in. The analysis of overall sentiment of trading Acrivon Therapeutics, Common stock suggests that some investors are interested at this time. Acrivon Therapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Acrivon Therapeutics,'s earnings reports, geopolitical events, and overall market trends.
Acrivon |
-Webcast investor event on September 14, 2024 at 900 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets ACR-368, ACR-2316, and its AP3 platform WATERTOWN, Mass., Sept. 09, 2024 -- Acrivon Therapeutics, Inc. , a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics platform for the discove
Read at finance.yahoo.com
 |
Acrivon Therapeutics, Fundamental Analysis
We analyze Acrivon Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Acrivon Therapeutics, is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Acrivon Therapeutics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acrivon Therapeutics, stock to make a market-neutral strategy. Peer analysis of Acrivon Therapeutics, could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics, by comparing valuation metrics with similar companies.
Peers
Acrivon Therapeutics, Related Equities
| RZLT | Rezolute | 5.10 | ||||
| ADAG | Adagene | 3.52 | ||||
| MOLN | Molecular Partners | 2.53 | ||||
| PMVP | Pmv Pharmaceuticals | 1.32 | ||||
| ANAB | AnaptysBio | 0.91 | ||||
| ANTX | AN2 Therapeutics | 0.72 | ||||
| AVTE | Aerovate Therapeutics | 0.38 | ||||
| MLYS | Mineralys Therapeutics, | 0.49 | ||||
| ANEB | Anebulo Pharmaceuticals | 5.95 | ||||
| OPT | Opthea | 6.11 |
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.